CGNH Stock Overview

Engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. More details

CGNH fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($14K)

Latest financial reports are more than a year old

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

CardioGenics Holdings Inc Competitors

Vaxxinity

OTCPK:VAXX

US$12.7k

Innovation Pharmaceuticals

OTCPK:IPIX

US$528.0

Molecular Templates

OTCPK:MTEM

US$2.0k

Histogen

OTCPK:HSTO.Q

US$122.6k

Price History & Performance

Summary of share price highs, lows and changes for CardioGenics Holdings
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	9,900.00%
3 Year Change	9,900.00%
5 Year Change	-98.00%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	CGNH	US Biotechs	US Market
7D	0%	-4.8%	-0.5%
1Y	9,900.0%	-3.2%	21.1%

Return vs Industry: CGNH exceeded the US Biotechs industry which returned -3% over the past year.

Return vs Market: CGNH exceeded the US Market which returned 23.1% over the past year.

Price Volatility

Is CGNH's price volatile compared to industry and market?
CGNH volatility
CGNH Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.3%
Market Average Movement	5.9%
10% most volatile stocks in US Market	18.2%
10% least volatile stocks in US Market	3.0%

Stable Share Price: CGNH's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine CGNH's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	n/a	Yahia Gawad	www.cardiogenics.com

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009.

CardioGenics Holdings Inc Fundamentals Summary

How do CardioGenics Holdings's earnings and revenue compare to its market cap?
CGNH fundamental statistics
Market cap	US$14.29k
Earnings (TTM)	-US$980.79k
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is CGNH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CGNH income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$980.79k
Earnings	-US$980.79k

Last Reported Earnings

Jan 31, 2016

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did CGNH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/12 04:34
End of Day Share Price	2024/12/19 00:00
Earnings	2016/01/31
Annual Earnings	2015/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CardioGenics Holdings Inc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Marckx	Zacks Investment Research Inc.